All cancers are fundamentally disorders of acquired defects in genes. The genes serve as blueprints for all of the components of cells and tissues in the human body. In cancers, faulty blueprints lead to malfunctioning cells that grow uncontrollably, spread throughout the body and overwhelm normal organ functions to threaten life itself. Full realization of(...)
Research
Cancer Research: Back to Basics
Posted by | ResearchMany types of cancer are caused by gene mutations acquired during a person’s lifetime. Systematic cataloging of these acquired gene defects has led to improved screening, detection, diagnosis, prevention and treatment. A more deliberate investment in discovery research could reveal more opportunities for developing cancer treatment by making better sense of the acquired gene defects(...)
New Test Detects Eight Cancer Types
Posted by | Prevention/Screening, Research, treatmentMay make the most feared disease a little less scary Cancer is scary. Part of the reason—maybe even the main reason—cancer is so scary, is that it seems to come out of nowhere and changes lives in the blink of an eye. We’re feeling fine, but under the surface, hidden within the DNA of our(...)
2017 in Review: Advances in Cancer Science and Medicine
Posted by | ResearchHere are our picks for the top stories: Mismatch Is Ideal Match for Immunotherapy: Our top pick was also selected by the New York Times as one of 17 things that happened for the first time in 2017. Ludwig Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy investigators linked a DNA spell-checklike error, known as mismatch(...)
2017 in Review: Honors and Awards
Posted by | Research, UncategorizedThe Kimmel Cancer Center was recognized with many honors and awards in 2017. Here’s the full list: Sidney Kimmel, leading cancer philanthropist for whom the Kimmel Cancer Center is named was honored with the American Association for Cancer Research Distinguished Public Service Award. He was recognized for his lifelong commitment to supporting advances in cancer(...)
Cancer Interception: Kimmel Experts Part of New Stand Up To Cancer Project
Posted by | Research, treatmentStand Up To Cancer launched four new teams aimed at detecting and treating cancer in its earliest stages. Lung cancer expert Julie Brahmer, M.D., is the lead investigator for Johns Hopkins for lung cancer studies based at the Kimmel Cancer Center Thoracic Center of Excellence she directs. Victor Velculescu, M.D., Ph.D., an expert in the(...)
A New Issue of Breast Matters
Posted by | Patient Stories, precision medicine, Prevention/Screening, Research, Survivorship, treatmentThe latest issue of Breast Matters is now out on newsstands, and we have it here for you in our brand new digital design. The new issue includes news on our GAITWAY Tumor board, a group of more than a dozen experts who match treatments to the unique genetic characteristics of patients’ tumors. It also(...)
What Every Lung Cancer Patient Needs to Know
Posted by | Research, treatmentIt’s lung cancer awareness month. “Many times patients come to us and they’ve been told they don’t have hope. We always have hope,” says Peggy Lang, nurse practitioner and coordinator of the Johns Hopkins Kimmel Cancer Center Thoracic Multidisciplinary Clinic and Lung Cancer Screening Program. In this video, she explains what every patient facing a(...)
Stand Up To Cancer Catalyst® Launches 10 Clinical Trial Projects
Posted by | ResearchJohns Hopkins Kimmel Cancer Center researchers and clinicians are among the leaders of one of the 10 Stand Up To Cancer (SU2C) Catalyst® clinical trial projects. Researchers from more than 30 institutions are collaborating across academic and corporate borders on clinical trials aimed at understanding why treatments are effective—across a variety of cancers—in a program(...)
Epigenetic Drugs Reset Genes in Breast, Colon Cancers But Didn’t Shrink Tumors
Posted by | Research, treatment--Two clinical trials suggest promise for using these medications in combination with other cancer therapies Two clinical trials using combinations of drugs meant to change cancer epigentics —or the way tumors express genes — failed at shrinking colon and breast tumors. However, these trials open the door for others currently in the works to combine(...)